Compare MBUU & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MBUU | IRWD |
|---|---|---|
| Founded | 1982 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 560.3M | 520.6M |
| IPO Year | 2014 | 2010 |
| Metric | MBUU | IRWD |
|---|---|---|
| Price | $33.80 | $5.45 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 5 |
| Target Price | ★ $33.88 | $5.74 |
| AVG Volume (30 Days) | 168.9K | ★ 7.4M |
| Earning Date | 01-30-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.98 | 0.18 |
| Revenue | ★ $830,714,000.00 | $338,987,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.92 | $37.22 |
| P/E Ratio | $34.24 | ★ $29.98 |
| Revenue Growth | ★ 11.54 | N/A |
| 52 Week Low | $24.07 | $0.53 |
| 52 Week High | $42.49 | $5.78 |
| Indicator | MBUU | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 66.22 | 77.47 |
| Support Level | $31.77 | $4.17 |
| Resistance Level | $34.44 | $4.80 |
| Average True Range (ATR) | 1.22 | 0.48 |
| MACD | 0.19 | 0.10 |
| Stochastic Oscillator | 86.15 | 81.68 |
Malibu Boats is a designer and manufacturer of power boats in the United States. It is a market leader in performance sport boats, sold under its Malibu and Axis brands. It acquired Cobalt Boats, a producer of sterndrive boats, in 2017, and Pursuit Boats, which makes high end offshore and outboard motorboats in 2018. In 2021, it purchased Maverick Boat Group, a seller of flat fishing boats, with exposure to bay, dual console, and center console boats. Malibu has also expanded into boat trailers and accessories, and in 2020, began producing its own engines for its performance sport boats.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.